Monte Rosa Therapeutics, Inc
A Drug Substance Development Scientist contributes to drug development from discovery to clinical and commercial stages, managing outsourcing activities, process development, and supply chain management. The role involves cross-functional collaboration and regulatory document preparation.
Monte Rosa Therapeutics is a biotechnology company pioneering molecular glue degrader (MGD) therapies that promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, traditionally undruggable proteins. Their drug discovery platform integrates expertise in MGD chemistry, artificial intelligence, structural biology, and proteomics to rapidly advance programs targeting undruggable or inadequately drugged targets with unprecedented specificity. Focused on cancer and beyond, the company operates out of Boston, MA and Basel, Switzerland.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc didn’t post a salary, so this is our estimate from similar listings.
Senior Director, Analytical Development, CMC Small Molecule
Centessa Pharmaceuticals
Director, CMC – Small Molecule Chemistry
Pathos
Associate Director, CMC Synthetic Chemistry – Small Molecule
Beeline Medicines
CMC & Manufacturing, Science and Technology Drug Substance Lead
Sobi
Senior Biotransformation Scientist
AstraZeneca
Senior / Executive Director of Chemistry, Manufacturing, and Controls (CMC)
Genesis Molecular AI